Tucker 2001.

Methods	Description: random‐assignment, placebo‐controlled, parallel arm, flexible‐dose, double‐blind, multi‐centre, 1 week placebo run‐in BLINDING Participants: Unclear Assessors: Unclear Administrators: Unclear ALLOCATION CONCEALMENT Method: Unclear RANDOMISATION Method: Unclear
Participants	SAMPLE Description: 323 DSM‐IV PTSD, 7% (21/307) combat‐related, mean age: 40.8 years, 66% female, average duration of diagnosis: 14.9 years, 35% (108/307) with comorbid major depression, baseline severity on CAPS‐2: paroxetine (73.2) and placebo (74.3) SCREENING Primary diagnosis: CAPS‐1; MINI, CAPS‐2 < 50 after placebo run‐in Comorbidity: Not mentioned
Interventions	Description: paroxetine 20 mg/d ‐50 mg/d (mean dose: 27.6 mg/d) versus placebo x 12 weeks
Outcomes	Primary outcomes: CAPS‐2 (score < 20 = 'remission'), CGI‐I Secondary outcomes: DTS, TOP‐8, SDS, MADRS Data estimation: LOCF (1 post‐baseline assessment)
Notes	INDUSTRY SUPPORT Industry funded: Yes Medication provided by industry: Unclear Any of the authors work for industry: Yes ADDITIONAL INFORMATION Drop‐out rates: 46% (70/151) on paroxetine and 42% (66/156) on placebo Quality rating score: 27
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	B ‐ Unclear